Assessment of Pathologic Complete Response of Breast Cancer with Different Molecular Subtypes after Neoadjuvant Chemotherapy with Dynamic Contrast-enhanced MR Imaging

Different molecular subtypes of breast cancer respond differently to neoadjuvant chemotherapy. Patients who achieve pathologic complete response (pCR) have better prognosis than non-pCR. In our study, semi-quantitative analysis of dynamic contrast-enhanced (DCE) MR Imaging between pCR and non-pCR was performed in four types of breast cancer (Luminal A, Luminal B, HER2+ and Triples negative), and our results showed that DCE-MR Imaging could become the potential predictor of pCR to NAC in breast cancer with Luminal B and Triples negative types. Maybe further study should be performed based on molecular subtypes of breast cancer.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.